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AbstrACt
Objectives The majority (>90%) of new or undiagnosed 
cases of hepatitis B virus (HBV) in the UK are among 
individuals born in countries with intermediate or 
high prevalence levels (≥2%). We evaluate the cost-
effectiveness of increased HBV case-finding among UK 
migrant populations, based on a one-time opt out case-
finding approach in a primary care setting.
Design Cost-effectiveness evaluation. A decision model 
based on a Markov approach was built to assess the 
progression of HBV infection with and without treatment as 
a result of case-finding. The model parameters, including 
the cost and effects of case-finding and treatment, were 
estimated from the literature. All costs were expressed in 
2017/2018 British Pounds (GBPs) and health outcomes as 
quality-adjusted life-years (QALYs).
Intervention Hepatitis B virus case-finding among UK 
migrant populations born in countries with intermediate 
or high prevalence levels (≥2%) in a primary care setting 
compared with no intervention (background testing).
results At a 2% hepatitis B surface antigen (HBsAg) 
prevalence, the case-finding intervention led to a mean 
incremental cost-effectiveness ratio of £13 625 per QALY 
gained which was 87% and 98% likely of being cost-
effective at willingness to pay (WTP) thresholds of £20 000 
and £30 000 per additional QALY, respectively. Sensitivity 
analyses indicated that the intervention would remain 
cost-effective under a £20 000 WTP threshold as long 
as HBsAg prevalence among the migrant population is at 
least 1%. However, the results were sensitive to a number 
of parameters, especially the time horizon and probability 
of treatment uptake.
Conclusions HBV case-finding using a one-time opt 
out approach in primary care settings is very likely to be 
cost-effective among UK migrant populations with HBsAg 
prevalence ≥1% if the WTP for an additional QALY is 
around £20 000.
IntrODuCtIOn
Worldwide, the burden of liver disease 
continues to rise and remains an urgent 
public health problem.1 It is estimated that 
viral hepatitis is in the top 10 leading causes 
of mortality globally,2 the majority due to 
infection with hepatitis B virus (HBV).3 
Chronic infection with HBV can lead to 
liver fibrosis, cirrhosis, hepatocellular carci-
noma (HCC) and death in the absence of 
treatment. It is estimated that over 5% of 
the world’s population are chronic carriers 
of HBV.4 Globally, HBV burden is highest in 
low-middle income countries in areas such as 
Sub-Saharan African and East Asia.3 HBV is 
spread through exposure to infected blood 
or body fluids, with the majority of chronic 
infections acquired perinatally or during 
childhood.1 Recently, effective antiviral treat-
ment for HBV has become available which 
may achieve long-term viral suppression and 
slow progression of disease.5 6
The UK has a low burden of HBV, with an 
estimated 0.4% of adults infected with chronic 
hepatitis B (CHB),7 and only approximately 
320 cases of acute HBV reported in England in 
20158. The vast majority (80%–90%) of newly 
diagnosed chronic HBV infections are among 
migrant individuals living in the UK that were 
strengths and limitations of this study
 ► Our cost-effectiveness evaluation is one of few stud-
ies evaluating hepatitis B virus case-finding among 
populations born abroad in intermediate to high en-
demicity countries.
 ► Strengths include numerous sensitivity analyses as-
sessing how cost-effectiveness varies for a range of 
different prevalences, intervention effect and cost, 
thus increasing the generalisability of our results to 
other similar interventions and different settings.
 ► A key limitation is uncertainty in the exact cost or 
effect of this intervention if scaled up to a national 
level.
 ► The model, due to a lack of available data, did not 
incorporate any additional impact of household con-
tact tracing of diagnosed cases.
 ► The model also does not incorporate the possibility 
of simultaneous testing for hepatitis C virus.
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born overseas in countries with intermediate (2%–7%) 
or high HBV prevalence (≥8%) as defined by the WHO,9 
such as China or Pakistan.10–12 Although uncertain, it is 
also likely that a considerable number of people with 
chronic HBV remain undiagnosed. For example, in one 
study in Bristol only 12% of migrants born in countries 
with endemic prevalence >2% had been tested for HBV.10 
Due to the often asymptomatic nature of chronic infec-
tion,13 individuals with HBV infection can often remain 
undiagnosed until they develop advanced liver disease. It 
is critical, therefore, that increased case-finding among 
UK migrant populations is enhanced to ensure timely 
treatment and follow-up to prevent complications from 
liver disease.
The UK, like many countries worldwide, recommends 
universal screening of pregnant women to identify and 
immunise neonates exposed to HBV infection, which has 
been shown to be highly cost-effective and under some 
circumstances cost-saving.14 However, the UK is one of 
only six countries in Europe which does not offer universal 
immunisation against hepatitis B (along with Denmark, 
Finland, Iceland, Norway and Sweden). These countries 
have a very low HBV endemicity and so it is unlikely to 
be cost-effective to introduce a separate universal HBV 
vaccination programme.15 Recent assessments of the 
cost-effectiveness of universal childhood HBV vaccination 
suggest that it may be cost-effective if introduced with 
other vaccines as a component of a hexavalent vaccine—
the UK moved to such a product in 2017.15 Nonetheless, 
infant vaccination is unlikely to have a great impact on 
the prevalence of chronic HBV in countries such as the 
UK because few transmissions are thought to occur once 
people have entered the country.16 For these reasons, 
there remains a critically important role for case-finding 
activities.
While studies in The Netherlands have shown the 
cost-effectiveness of one-time screening programmes 
(where a test offer is mailed to migrant individuals iden-
tified through a population registry17), until recently 
there has not been a published evaluation from a UK 
perspective. This changed earlier this year when the 
results of a randomised controlled trial (HepFREE) 
showed that incentivised screening of HBV and hepatitis 
C virus (HCV) in first-generation and second-generation 
migrants in a primary care setting was shown to be effec-
tive and cost-effective in the UK; the incentive included a 
startup payment of £500 per general practice (GP), £25 
for each enrolled participant and support from a dedi-
cated clinician 3 days a week.18 However, in contrast to an 
incentivised screening approach, pilot data from the UK 
also indicate that an opt-out HBV case-finding approach 
in primary care settings without incentives was also highly 
effective, and potentially a less expensive approach.19 
Additionally, it was unclear in the previous analysis for 
the HepFREE trial how much the cost-effectiveness was 
driven by HCV versus HBV outcomes, and whether the 
intervention was cost-effective for HBV alone. Further, it is 
unknown how the cost-effectiveness of HBV case-finding 
could vary for a range of prevalences (which likely vary by 
country of origin), costs and uptake rates that may occur 
when the interventions are rolled out across different 
settings.
The aim of this paper is to evaluate the cost-effective-
ness of increased HBV case-finding among UK migrant 
populations born in intermediate or high endemicity 
countries, based on a one-time opt out case-finding 
approach in primary care settings. Importantly, to 
increase the generalisability of our results to other similar 
interventions and different settings, we assess how the 
cost-effectiveness of HBV case-finding varies for a range 
of different prevalences, intervention effect and cost.
MethODs
The economic evaluation was undertaken using a Markov 
approach, where a closed cohort of UK individuals 
born in countries with intermediate or high prevalence 
levels (≥2%) move between a set of discrete health states 
representing HBV infection stage.20 21 A UK National 
Health Service’s cost perspective was used. All costs were 
displayed in British Pounds (GBPs), 2017/2018 prices 
and a 40-year time horizon was used with an annual time 
step. Health outcomes were expressed in terms of qual-
ity-adjusted life-years (QALYs). QALYs and costs were 
discounted at 3.5% per annum according to UK National 
Institute for Health and Care Excellence (NICE) recom-
mendations.22 Uncertainty in the results was examined 
using deterministic and probabilistic sensitivity analysis 
(PSA); distributions shown in the tables relate to the PSA 
analysis. Each PSA consisted of 5000 runs. HBV transmis-
sion was not included in the model as most infections are 
likely to occur in UK migrant populations before entering 
the UK.16 
Intervention and target population
A systematic literature review found few studies evaluating 
HBV case-finding in migrant or other high-risk popula-
tions, nor have many studies been published since this 
review.18 23 Our study evaluates the cost-effectiveness of 
HBV case-finding in the UK for individuals born in coun-
tries with intermediate or high prevalence levels (≥2%). 
The base case analysis uses the results from an uncon-
trolled study in which Pakistani/British Pakistani people 
registered at GPs in London’s East End were written to 
and invited to ‘opt out’ of being tested for hepatitis B and 
C infection. Those who did not opt out were telephoned 
and asked to attend a clinic for testing.19 The interven-
tion was designed to increase the likelihood of testing for 
each infection, assumed in this analysis to occur over the 
initial model cycle of 1 year. After this time, the interven-
tion effect was assumed to be zero, with the probability 
of testing reverting to background levels. The compar-
ator programme or ‘no intervention’ was defined as the 
background likelihood of testing through existing routes 
such as sexual health or genitourinary medicine clinics, 
antenatal clinics or primary care.24 Although we base our 
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analysis on data from a study among Pakistani/British 
Pakistani individuals in London, we evaluate the potential 
impact of this intervention in populations with a range of 
HBV prevalences as observed among UK migrants born 
in countries with intermediate or high prevalence levels 
(≥ 2%).
Model structure
The Markov model was created to represent HBV 
disease progression and current understanding of poli-
cies regarding disease management (figure 1). The 
natural history element of the model was largely based 
on a model developed by Shepherd et al.25 26 The model 
simulates a cohort of people, a proportion of whom are 
positive for hepatitis B surface antigen (HBsAg+). For this 
analyses, we refer to ‘HBV prevalence’ as the proportion 
of individuals who are HBsAg+. Individuals who are nega-
tive for HBsAg- remain in the model with a general popu-
lation level of mortality but incurring no HBV-related 
costs, other than the possibility of being tested for infec-
tion. Known HBsAg+ people were assumed to undergo 
a full viral profile when initially diagnosed. Acute HBV 
infection was not included in the model as it is likely that 
people would have been infected much longer than 6 
months ago.
Among HBsAg+ individuals, the model stratifies by 
mutually exclusive stages of CHB, including HBeAg sero-
converted (where ALT (alanine aminotransferase) levels 
and HBV DNA are both low), active CHB hepatitis B e-an-
tigen positive (HBeAg+) disease, active CHB hepatitis B 
e-antigen negative (HBeAg-) disease and inactive CHB 
HBeAg- (where ALT levels and HBV DNA are both 
low). Individuals progressed from CHB to compensated 
cirrhosis, decompensated cirrhosis (DC), HCC, liver 
transplant and post-transplant stages if appropriate drug 
treatment was not initiated or failed. Due to the severity of 
the disease and likely presentation, the infection status of 
all individuals with CHB was assumed to become known 
when they developed DC, HCC or required a liver trans-
plant. Individuals could die from non-HBV related causes 
from any health state.
Individuals who had raised ALT and HBV (active) 
levels and who were CHB HBeAg+ were assessed for 
fibrosis and offered treatment with pegylated interferon 
for the first year, followed by tenofovir until serocon-
version is achieved (as per NICE guidelines27) or later 
stage CHB developed. We assumed successful treatment 
of these individuals resulted in normalisation of ALT 
and lowering of HBV DNA levels, therefore resulting in 
transition to the HBeAg seroconverted stage. Individ-
uals with no evidence of compensated cirrhosis stopped 
treatment at this time.27 Individuals with active CHB who 
were HBeAg- also received pegylated interferon for the 
first year, followed by tenofovir if they had not developed 
inactive CHB HBeAg- disease.27 However, even following 
the development of inactive disease, they were assumed 
to stay on treatment indefinitely to sustain the achieved 
level of viral suppression.27 Individuals with evidence 
of compensated cirrhosis were assumed to remain on 
tenofovir as long as no further disease progression was 
recorded, irrespective of e-antigen status.27 All individuals 
were assumed to stop treatment on progression to DC or 
later stages of disease.
Individuals with CHB whose infection status was 
unknown and those that tested HBsAg+, but declined 
treatment, were assumed to develop progressive disease 
according to a set of defined transition probabilities, 
with different probabilities used for those who accepted 
treatment (online supplementary tables 1 and 2). As the 
focus of this analysis is on case-finding, we do not model 
possible adverse events associated with treatment or treat-
ment resistance.
Model parameters
HBV prevalence among migrant populations to the UK
There is substantial heterogeneity in HBV burden between 
different migrant populations in the UK depending on 
their country of origin. Additionally, HBV prevalence 
among UK migrants may be different compared with 
their country of origin; a recent UK study of antenatal 
testing showed the prevalence in migrants was generally 
less than published estimates for the country of origin, 
with only Eastern Asia having a higher than expected 
prevalence.11 Public Health England (PHE) data on those 
undergoing routine diagnostic testing suggest that the 
HBV prevalence among all Asian or British Asian people 
in the UK is approximately 2%; however, these data 
do not specify country of origin in any further detail.28 
Figure 1 HBV model schematic. The arrows denote 
possible transitions between states. CC, compensated 
cirrhosis; CHB, chronic hepatitis B virus; DC, decompensated 
cirrhosis; HBeAg, hepatitis b virus e antigen; HBsAg, hepatitis 
B virus surface antigen; HCC, hepatocellular carcinoma; 
LT, liver transplant; *individuals may or may not know 
their infection status. %Individuals with CC responding 
to treatment were assumed to keep the costs and 
utility associated with CC, but with disease progression 
probabilities equivalent to HBeAg seroconversion/
inactive disease. †Transitions permitted from all health states 
to death.
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By contrast, the HBV prevalence estimates obtained 
through targeted studies or antenatal testing have iden-
tified a range of prevalence among UK migrants born in 
countries with intermediate-high HBV endemicity, such 
as 17% (Vietnam-born), 7%–10%29 30 (China-born), 
3%–6% (Somalia-born), 1%–3% (Pakistan-born), 0.5%–
1.5% (Bangladesh-born), 0.7% (Poland-born) and 0.5% 
(India-born).16 31–33 The recent HepFREE trial found a 
lower prevalence of 1.1%, varying by country of origin, 
although this included second-generation migrants that 
were born in the UK.18
Due to the uncertainty in prevalence within popula-
tions, and the likely wide variation between populations, 
in the base case, we assume an HBV prevalence (HBsAg+) 
of 2%, but explore a range of values (from 0.05% to 10%) 
in the sensitivity analysis.
Transition probabilities
Transition probability values, representing the likelihood 
of moving between health states, for untreated disease 
stages were based on those reported in a 2006 UK Health 
Technology Assessment report (online supplementary 
tables 1 and 2).25
Background testing rate and diagnostic accuracy
The background rate of testing for migrants in the absence 
of the intervention was estimated using data from PHE, 
indicating a probability of 2.6% per year.24 The HBsAg 
diagnostic test was assumed to be 100% accurate.
Referral and treatment effect
Few studies have quantified the number of people diag-
nosed with CHB who are subsequently referred to, and 
accept, appropriate further clinical investigations for 
their infection. However, interruptions in the cascade 
of care postdiagnosis are known to be an issue in the 
management of CHB and HCV infection both in the UK 
and elsewhere, particularly in migrant populations.34 We 
therefore include a single probability of being referred for 
specialist care following a HBsAg+ test result, attending 
the appointment and starting treatment for those eligible. 
In the absence of HBV-related data, we use data on the 
proportion of individuals who were identified using algo-
rithmic approaches as being Asian and who tested posi-
tive and subsequently received treatment for chronic 
HCV from 2004 to 2015 (0.42, based on data supplied by 
PHE, personal communication with PHE staff). However, 
we consider this parameter to be highly uncertain and 
undertake sensitivity analysis around it using a wide range 
of alternative values (10% to 60%).
While a systematic review and meta-analysis of the 
effects of drug therapy for CHB is available,35 we estimated 
the impact of antiviral treatment using data from a study 
which has a much longer follow-up period (5 years rather 
than 1 year).36 For HBeAg+ individuals, we assumed 20% 
would e-antigen seroconvert after 1 year of treatment with 
pegylated interferon and 5.4%/year following treatment 
with tenofovir, resulting in 40% having seroconverted 
by 5 years. For HBeAg- individuals, we assumed a 75% 
probability of response (development of inactive disease) 
following the initial 1 year of pegylated interferon and 
2.3%/year following treatment with tenofovir. There-
fore, we assumed that 84% would develop inactive disease 
by 5 years. Irrespective of whether individuals were 
HBeAg+ or HBeAg-, they were assumed to continue treat-
ment after 5 year with tenofovir until they responded to it 
assuming the same constant rate of response.
The probability of responding to treatment was assumed 
to be the same for people with or without compensated 
disease. However, once people developed compensated 
disease, it was assumed not to regress following treat-
ment, and the costs and disutility associated with it would 
remain. The only benefit of treatment in this group was 
slower progression to poorer health states compared with 
not being treated.
Intervention effect
The base case probability of testing for HBsAg in the 
intervention arm was based on a one-time ‘opt out’ 
option within a GP setting; 223 out of 1134 (19.7%) 
eligible tested after being identified using a GP regis-
tries database and responding to a written invite.19
Cohort demographics and initial stage distribution
PHE data suggest that the average age at HBV diagnosis 
in the UK Asian population is approximately 35 years of 
age,28 which we use as the base-case starting age in our 
model but vary in the sensitivity analysis. The propor-
tion of people with CHB who were HBeAg+ in our 
starting cohort was assumed to be 0.14 ((71/490) 
personal communication with PHE staff). The propor-
tion of people who had seroconverted, or developed 
inactive disease, before being tested for HBsAg, was 
assumed to be 80% (personal communication with 
PHE staff). It was further assumed that 44% of people 
with active HBeAg+ or HBeAg- disease had already 
developed compensated cirrhosis.37
Health utilities and costs
Utility values related to HBV infection were sourced 
from the review by Shepherd et al25 and Takeda et 
al26 (online supplementary table 3). The costs of 
HBV testing/monitoring, antiviral treatment and 
health-state specific costs were taken from a number 
of published sources25 37 (table 1), inflated to GBP 
£2017 where appropriate using the NHS Hospital and 
Community Health Services Pay and Prices Index and 
the Health Service Cost Index.38 39 The intervention 
cost was estimated at £4 per person eligible for testing. 
This cost relates to the resources required to identify 
and invite each individual for a test and excludes the 
cost of any tests and treatments. Thus, if 100 indi-
viduals were eligible for testing, the total cost of the 
intervention was £400 irrespective of how many people 
attended for a test. The importance of this assumption 
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was assessed in the sensitivity analysis given the extent 
of uncertainty.
Main outcomes
Our main results incorporate a PSA, in which relevant param-
eters are simultaneously sampled 5000 times to represent 
underlying uncertainty, including the costs, utilities, prob-
abilities and disease progression parameters. We present 
total and incremental costs, QALYs and incremental cost-ef-
fectiveness ratios (ICERs). Mean and 2.5%–97.5% centile 
(95% CI) results are presented. We additionally present the 
proportion of simulations which are cost-effective under 
£20 000 and £30 000 willingness to pay (WTP) per additional 
QALY thresholds.
sensitivity analyses
To test the robustness of the results to alternative assump-
tions, we undertook extensive one-way sensitivity analyses 
on starting age, discount rate, drug cost, time horizon, 
treatment uptake, intervention effect and intervention cost. 
Finally, due to the uncertainty surrounding the intervention 
cost and impact if scaled-up to the national level and among 
different migrant populations, we undertook a threshold 
analysis where we evaluated the minimum HBV prevalence 
at which the intervention remains cost-effective at a WTP 
threshold of <£20 000 per QALY gained with varying inter-
vention cost (between £1 and £20, £4 per person eligible 
at base-case), intervention effect (between 5% and 30%, 
19.7% uptake at base-case) and HBsAg prevalence (between 
1% and 10%, 2% base-case). We displayed the results of this 
sensitivity analysis as a contour map.
results
base-case 2% hbsAg prevalence
At a 2% HBsAg prevalence, the HBV case-finding inter-
vention resulted in mean incremental costs and QALYs 
of about £28 and 0.002, respectively, over the 5000 
samples, corresponding to an ICER of £13 625 per QALY 
gained (95% CI £7121–£27 588). The intervention was 
87% and 98% likely to be cost-effective at £20 000 and 
£30 000 WTP per additional QALY thresholds, respec-
tively (online supplementary figure 1). Most of the 
univariate sensitivity analyses produced ICERs below a 
£20 000 WTP threshold (figure 2), including reducing 
the likelihood of testing from 19.7% to 5% (£19 323/
QALY gained). However, the exceptions were assuming 
a 20-year time horizon instead of 40 years (£22 713/
QALY gained), discounting QALYs at 6% instead of 3.5% 
(£21 970/QALY gained), not discounting costs instead 
of 6% (21 521/QALY gained) and doubling the costs of 
all drug treatments from £3979/£2453 to £7957/ £4905 
(£22 586/QALY gained). Decreasing the probability of 
treatment uptake after testing positive for HBsAg from 
0.42 to 0.1 increased the ICER to over £30 000 (£31 340/
QALY gained).
Impact of variation in hbV prevalence and intervention impact 
(cost, effect and uptake)
Cost-effectiveness of HBV case-finding was strongly driven 
by HBV prevalence. Our sensitivity analyses indicated 
that the intervention would remain cost-effective under 
a £20 000 WTP threshold as long as HBV prevalence 
among the migrant population is equal to or exceeds 1% 
(figure 3).
Table 1 Annual costs in 2017/2018 UK prices (£)
Cost Mean
95% interval of sampled 
range* Source
Intervention cost per person eligible for testing† 4 – Assumption
HBsAg test (laboratory) 10 – Assumption
Pegylated interferon 3979 – BNF45
Tenofovir 2453 – BNF45
ALT and ultrasound 77 – Assumption45
Full viral profile 432 – Assumption45
HBeAg+ seroconverted/ HBeAg- ALT/DNA low* 335 240–446 Shepherd25
HBeAg+/HBeAg active disease§ 674 480–896 Shepherd25
Compensated cirrhosis 1606 1052–2283 Crossan37
Decompensated cirrhosis 38 212 21 848–60 645 Crossan37
Hepatocellular carcinoma 38 212 21 848–60 645 Crossan37
Liver transplant (first year) 67 698 57 301–79 287 Crossan37
Liver transplant (subsequent years) 17 231 5415–35 399 Crossan37
*Sampled values from the probabilistic sensitivity analysis using a gamma distribution.
†One off cost.
§Costs are additional to*.
BNF, British National Formulary; HBeAg, hepatitis b virus antigen; HBsAg, hepatitis B virus surface antigen.
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Due to the uncertainty in cost and intervention impact 
if scaled-up across the UK and among different migrant 
population, we additionally present a sensitivity analysis 
of the threshold HBV prevalence which would ensure 
that the intervention is cost-effective under a £20 000 WTP 
with varying costs and intervention effects (figure 4). The 
contour map shows that, for example, the intervention 
would be cost-effective at a prevalence of 1% if it cost £6 
per person and the intervention effect was 20%. However, 
it would no longer be cost-effective at a 1% prevalence 
level and £6 cost if the intervention effect reduced to 
10%.
DIsCussIOn
HBV case-finding using a one-time opt out approach in 
primary care settings has a high potential to be cost-ef-
fective among UK migrant populations with a HBV 
prevalence at or above an average of 1%. However, the 
results are sensitive to a number of factors including the 
intervention effect and cost, rate of treatment uptake, 
assuming a much shorter time horizon and (unrealisti-
cally) high discount rates and drug costs.
limitations
The main limitation with the analysis is the substantial 
uncertainty surrounding the costs of the intervention and 
its effect if this case-finding intervention were scaled-up 
to a national level. Nonetheless, extensive sensitivity anal-
ysis shows that the intervention remained cost-effective 
across a large range of evaluated scenarios. Thus, while 
establishing more robust estimates of the costs and effects 
of interventions to find cases of HBV will undoubtedly 
decrease the uncertainty around our results, we believe 
that the scope for the modelled intervention to be cost-ef-
fective is extremely high.
Current UK NHS HBV-testing policy is to contact house-
hold members once a case has been identified. However, 
we were unable to include this aspect in our analysis due 
to a lack of data specific to the target migrant popula-
tions on the size and age distribution of households of 
infected contacts, the probability that contacts were 
HBsAg+ and the likelihood that contacts could be traced 
in the first instance. The impact of excluding this process 
Figure 2 Univariate sensitivity analysis on the ICER with a 2% HBV prevalence scenario. Y-axis indicates the base case ICER 
of £21 400 per QALY gained.HBV, hepatitis B virus; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year. 
*Halves or doubles all baseline drug costs where relevant.
Figure 3 Mean incremental cost-effectiveness ratio (ICER) 
of HBV screening by varying HBsAg prevalence. HBsAg, 
hepatitis B surface antigen;  QALY, quality-adjusted life-year. 
Figure 4 Contour map showing for a range of costs 
(horizontal axis) and intervention effects (vertical axis), 
the threshold HBV prevalence (contours) where the 
intervention ICER falls under a £20 000 willingness to pay 
threshold. HBV, hepatitis B virus;  ICER, incremental cost-
effectiveness ratio.
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on the ICER we report is difficult to determine. For 
example, if contact tracing results in a high proportion of 
people being treated for CHB, the ICER could decrease. 
Conversely, if many HBsAg- people are vaccinated against 
HBV, the ICER could increase as there is already evidence 
to suggest it is unlikely to be cost-effective.15
Finally, we did not model the possibility of simultane-
ously testing for HCV, which may increase the cost-effec-
tiveness of the intervention though evidence on the HCV 
prevalence among migrants also has uncertainies.19
Comparison with other studies
Five studies have examined the cost-effectiveness of 
screening for HBV among migrant populations. A Dutch 
study17 found that screening migrants from countries with 
high or intermediate HBV prevalence (assuming a 3.4% 
chronic infection prevalence) was highly cost-effective 
(EUR9000 per QALY gained) at a screening campaign 
cost of approximately EUR11 per person eligible and 
35% uptake—which is consistent with our sensitivity anal-
ysis. Another study explored screening and treatment of 
migrants from Asian and Pacific Islands in the USA,40 
finding it to be cost-effective (US$36 000 per QALY 
gained) but also assuming a much higher prevalence of 
HBV (10%), screening uptake (70%) and no screening 
programme costs aside from the diagnostic tests. Two 
studies examined the cost-effectiveness of screening all 
migrants to Canada,41 42 both finding tenofovir-based 
treatment moderately cost-effective (CAD$40 000/QALY 
(~£22 000)) at 4.8%–6.5% chronic infection prevalence’s. 
Our model assumes a lower prevalence of chronic HBV, 
higher treatment efficacy and lower treatment and 
screening costs than the North American studies, which 
may explain the difference in cost-effectiveness estimates. 
Finally, our results are partially consistent with findings 
from the recent HepFREE trial, which was found to be 
cost-effective (£8540/QALY) for a similar observed inter-
vention effect (19.7% uptake of testing compared with 
19.5% uptake in our study). However, HepFREE had 
higher intervention costs (>£25 per patient compared 
with £1–£20 in our model), combined HCV and HBV 
screening and identified patients on basis of ethnic group 
rather than country of birth.43
COnClusIOns
Our analysis suggests that interventions to increase HBV 
case-finding in primary care among UK migrant popu-
lations with a prevalence of at least 1%—such as using 
a one-time opt out approach— could be cost-effective, 
underpinning current NIHC guidance.44 Critically, at 
a threshold prevalence above 1%, this will encompass 
migrant populations from most countries with endemic 
HBV, even if there is a healthy migrant effect (with 
migrant populations in UK on average at lower risk 
than people in their country of origin16). These recent 
results support the recommendation that interventions 
to increase HBV case-finding in primary care among UK 
migrant populations should be expanded, but needs to 
be based on screening by country of birth rather than 
ethnic group.
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